Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3.65% Impact
03:05pm, Friday, 14'th Nov 2025
Insights into Stanley Druckenmiller (Trades, Portfolio)'s Third Quarter 2025 Portfolio Adjustments Stanley Druckenmiller (Trades, Portfolio) recently submitted
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
07:00am, Thursday, 13'th Nov 2025
More than 1,200 employees across the U.S., Europe, and Japan unite to support multiple organizations during annual company-wide day of service BRIDGEWATER, N.J. , Nov. 13, 2025 /PRNewswire/ -- Insme
Artisan Global Opportunities Fund Q3 2025 Portfolio Update
08:10am, Thursday, 06'th Nov 2025
During the quarter, we initiated new positions in Spotify, L3Harris Technologies and Insmed. We also added to 3i Group, West Pharmaceutical and Amazon during the quarter. We ended our investment campa
American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors
08:10am, Wednesday, 05'th Nov 2025
Google's parent company received a relatively benign antitrust ruling that would not force Alphabet to sell its Chrome browser or Android operating system. Alnylam's shares benefited from a positive p
Insmed To Present at November and December 2025 Investor Conferences
07:00am, Wednesday, 05'th Nov 2025
BRIDGEWATER, N.J. , Nov. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Latest read on rare disease gene therapy from Insmed CEO Will Lewis
06:13pm, Monday, 03'rd Nov 2025
Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
10:01am, Friday, 31'st Oct 2025
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript
11:16am, Thursday, 30'th Oct 2025
Insmed Incorporated ( INSM ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Bryan Dunn - Vice President of Investor Relations William Lewis - President, CEO & Chairman Roger A
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
09:20am, Thursday, 30'th Oct 2025
Insmed (INSM) came out with a quarterly loss of $1.75 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.27 per share a year ago.
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
07:00am, Thursday, 30'th Oct 2025
—BRINSUPRI ™ (brensocatib ) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Jap
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics
10:16am, Wednesday, 29'th Oct 2025
Beyond analysts' top-and-bottom-line estimates for Insmed (INSM), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter e
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
01:27pm, Monday, 27'th Oct 2025
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
04:05pm, Thursday, 23'rd Oct 2025
—Insmed Leads Science Top Employers List for Fifth Year in a Row— BRIDGEWATER, N.J. , Oct. 23, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical co
Analysts Estimate Insmed (INSM) to Report a Decline in Earnings: What to Look Out for
11:00am, Thursday, 23'rd Oct 2025
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blue Trust Inc. Decreases Stake in Insmed, Inc. $INSM
03:40am, Sunday, 19'th Oct 2025
Blue Trust Inc. lowered its position in Insmed, Inc. (NASDAQ: INSM) by 37.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 564 shares of the
